


## PHARMACEUTICAL 2018

## **Aanixa**

## Anixa Biosciences Inc Rank 87 of 342





## PHARMACEUTICAL 2018

Rank 87 of 342





The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Anixa Biosciences Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 178%, being 132% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	7,014
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	889
Liabilities, Non-Current	0
Other Assets	1,746
Other Compr. Net Income	0
Other Expenses	930
Other Liabilities	0
Other Net Income	1,567
Other Revenues	362
Property and Equipment	53
Research and Development	1,598
Selling, General and Administrative Expense	4,411

Output Variable	Value in 1000 USD
Assets	8,812
Liabilities	889
Expenses	6,939
Revenues	362
Stockholders Equity	7,923
Net Income	-5,009
Comprehensive Net Income	-5,009
Economic Capital Ratio	178%

